TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
37 hedge funds and large institutions have $34.4M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
12% more funds holding
Funds holding: 33 → 37 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
24% less capital invested
Capital invested by funds: $45.1M → $34.4M (-$10.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$204K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$116K |
| 3 |
Goldman Sachs
New York
|
+$61.6K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$49.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$47.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$270K |
| 2 |
TI
Telemetry Investments
New York
|
-$162K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$80.6K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$71.8K |
| 5 |
Millennium Management
New York
|
-$55.6K |
TCON Hedge Fund Activity: Q3 2018 in Review
37 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2018, worth a combined $34.4M — down 24% from $45.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TCON positions and 1 closed out — a net gain of 4 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $204K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $270K sold.
- 37 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2018, up from 33 in Q2 2018.
- Funds reported $34.4M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2018, down 24% quarter-over-quarter.
- 5 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 1 closed out, a net change of +4 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was Renaissance Technologies, an estimated $204K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Alyeska Investment Group, an estimated $270K sold.
Based on aggregated 13F filings for Q3 2018.